| Theme | Gastroenteropancreatic Neuroendocrine Tumors | |
|---|---|---|
| Title | Insulinoma | |
| Publish Date | 2013/01 | |
| Author | Tatsuya Ito | Surgical Oncology and Gastrointestinal Surgery, Sapporo Medical University / Department of Surgery, Hokkaido Prefectural Esashi Hospital |
| Author | Yasutoshi Kimura | Surgical Oncology and Gastrointestinal Surgery, Sapporo Medical University |
| Author | Masafumi Imamura | Surgical Oncology and Gastrointestinal Surgery, Sapporo Medical University |
| Author | Hiroshi Yamaguchi | Surgical Oncology and Gastrointestinal Surgery, Sapporo Medical University / Department of Surgery, Kouiki Mombetsu Hospital |
| Author | Daisuke Kyuno | Surgical Oncology and Gastrointestinal Surgery, Sapporo Medical University |
| Author | Shigenori Ota | Surgical Oncology and Gastrointestinal Surgery, Sapporo Medical University |
| Author | Koichi Hirata | Surgical Oncology and Gastrointestinal Surgery, Sapporo Medical University |
| [ Summary ] | Insulinoma is due to insulin producing tumors derived from islet β-cells. They are one of the most representive type of pancreatic neuroendocrine tumor (PNET). Many are solitary and benign. However, some are difficult to detect due to localization or display malignant behavior. Hypoglycemia from hypoinslinism is a typical symptom of insulinoma. Surgical resection is the standard treatment for insulinoma. Many of these tumors are resected with enucleation. However, multiple or malignant insulinomas are resected employing pancreatectomies. Unresectable insulinoma is treated with somatostatin analogs, chemotherapy or molecular targeted therapy. | |